Notice Regarding Transfer of Shares of Eisai Subsidiaries
January 31, 2015     Japanese 
	  Network - Home
JCN Newswire
  Home  |  Companies  | Annual Reports  |  CSR  | News Alerts     
Notice Regarding Transfer of Shares of Eisai Subsidiaries - JCN Newswire
Notice Regarding Transfer of Shares of Eisai Subsidiaries

Tokyo, Feb 9, 2012 - (JCN Newswire) - Eisai Co. Ltd entered into an asset purchase agreement with Robert Bosch GmbH (Bosch Group) on February 8, 2012 concerning the transfer of the entire stock and equity interest (100% of total shares issued or equity interest) of the four subsidiaries that comprise the Eisai Group's machinery business to Bosch Group.

Under the terms of this agreement, the Eisai Group plans to transfer 100% of total shares held in Eisai Machinery Co. Ltd, the Group's Japan pharmaceutical machinery subsidiary and the sole owner of China-based Eisai Machinery Shanghai Co. Ltd, to Bosch Packaging K.K. The Group will also transfer its interest in its U.S. pharmaceutical machinery sales subsidiary Eisai Machinery U.S.A. Inc. to Robert Bosch North America Corp. as well as its 100% equity interest in European-based Eisai Machinery GmbH to Robert Bosch GmbH. The transfer of all shares and equity from all four subsidiaries is scheduled to take place on March 30, 2012.

Reasons for the Transfer of Sales

Eisai Machinery Co. Ltd is a wholly-owned subsidiary of Eisai Co. Ltd that was established in 1964 by Health Co. Ltd and merged with Eisai's Machinery Business (absorption type company split) in 2004. The company is engaged in the manufacture, sales and export of pharmaceutical machinery as well as sales of packaging materials. Eisai Machinery Co. Ltd, Eisai Machinery U.S.A. Inc., Eisai Machinery GmbH and Eisai Machinery Shanghai Co. Ltd (four companies hereinafter collectively referred to as Eisai Machinery) are responsible for global sales of pharmaceutical machinery and have made substantial contributions to quality inspection at pharmaceutical companies worldwide. As a member of Eisai Group, Eisai Machinery has established an operational presence by overseeing the entire process from development through production, marketing, and after-sales service of liquid formulation inspection machines and other machinery as it seeks to enhance corporate value through the provision of high-quality and highly-sophisticated manufacturing line machinery, such as its Automatic Inspection Machine (AIM), for use in the production of pharmaceuticals.

The Eisai Group believes that given the increasingly severe conditions in the pharmaceutical machinery market, it is essential that Eisai Machinery form a strategic alliance with a company that possesses state-of-the-art production technology and know-how in order to be able to ensure the continuous delivery of new and innovative products to the global market. The Group believes that the Bosch Group's presence in the global market as well as its pharmaceutical packaging machinery-related technology and knowledge will create great synergy that will ensure the future prosperity of Eisai Machinery, and has therefore decided to transfer the entire share and equity interest from all four subsidiaries to Bosch Group. This agreement will enable the Eisai Group to further focus its resources on its pharmaceutical business in order to accelerate innovation and enhance corporate value.

About Eisai

Eisai Co., Ltd. (TSE: 4523; ADR: ESALY) is a research-based human health care (hhc) company that discovers, develops and markets products throughout the world. Eisai focuses its efforts in three therapeutic areas: integrative neuroscience, including neurology and psychiatric medicines; integrative oncology, which encompasses oncotherapy and supportive-care treatments; and vascular/immunological reaction. Through a global network of research facilities, manufacturing sites and marketing subsidiaries, Eisai actively participates in all aspects of the worldwide healthcare system. For more information about Eisai Co., Ltd., please visit


Public Relations Department
Eisai Co. Ltd
T: +81-(0)3-3817-5120

Feb 9, 2012
Source: Eisai

Eisai (TSE: 4523) (U.S: ESALY)

From the Japan Corporate News Network
Topic: Merger & Acquisition
View more news from these Sectors: Biotech, Drugs & OTC

CSR Report Download
Annual Reports

  More >>    
Most Popular

About JCN | Privacy Policy | Terms of Use | JCN Network (日本語)